These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38703312)

  • 1. Comparators in Pharmacovigilance: A Quasi-Quantification Bias Analysis.
    Gravel CA; Bai W; Douros A
    Drug Saf; 2024 Aug; 47(8):809-819. PubMed ID: 38703312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active-comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: An example using sodium/glucose cotransporter 2 inhibitors.
    Alkabbani W; Gamble JM
    Br J Clin Pharmacol; 2023 Feb; 89(2):431-439. PubMed ID: 34964156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.
    Raschi E; Poluzzi E; Koci A; Salvo F; Pariente A; Biselli M; Moretti U; Moore N; De Ponti F
    Br J Clin Pharmacol; 2015 Aug; 80(2):285-93. PubMed ID: 25689417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Considerations on the use of different comparators in pharmacovigilance: A methodological review.
    Gravel CA; Douros A
    Br J Clin Pharmacol; 2023 Sep; 89(9):2671-2676. PubMed ID: 37226576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting system.
    Sun C; Yang X; Tang L; Chen J
    Expert Opin Drug Saf; 2024 Aug; 23(8):1049-1060. PubMed ID: 37898875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on Food and Drug Administration adverse event reporting system data.
    Wei C; Liu Y; Jiang A; Wu B
    Int J Clin Pharm; 2022 Jun; 44(3):709-716. PubMed ID: 35364753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
    Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-induced liver injury associated with elexacaftor/tezacaftor/ivacaftor: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS).
    Shi A; Nguyen H; Kuo CB; Beringer PM
    J Cyst Fibros; 2024 May; 23(3):566-572. PubMed ID: 38233246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system.
    Fan Q; Ma J; Zhang B; Li Q; Liu F; Zhao B
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):655-662. PubMed ID: 33001273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system.
    Orogun L; Chyou TY; Nishtala PS
    Int J Risk Saf Med; 2023; 34(2):87-99. PubMed ID: 37154187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surveillance of drugs that most frequently induce acute kidney injury: A pharmacovigilance approach.
    Hosohata K; Inada A; Oyama S; Furushima D; Yamada H; Iwanaga K
    J Clin Pharm Ther; 2019 Feb; 44(1):49-53. PubMed ID: 30014591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
    Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
    Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibacterial-associated acute kidney injury among older adults: A post-marketing surveillance study using the FDA adverse events reporting system.
    Chinzowu T; Chyou TY; Nishtala PS
    Pharmacoepidemiol Drug Saf; 2022 Nov; 31(11):1190-1198. PubMed ID: 35670078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-epidemiological study found lack of transparency and poor reporting of disproportionality analyses for signal detection in pharmacovigilance databases.
    Khouri C; Revol B; Lepelley M; Mouffak A; Bernardeau C; Salvo F; Pariente A; Roustit M; Cracowski JL
    J Clin Epidemiol; 2021 Nov; 139():191-198. PubMed ID: 34329725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
    Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute kidney injury following SGLT2 inhibitors among diabetic patients: a pharmacovigilance study.
    Chen G; Li X; Cui Q; Zhou Y; Zhao B; Mei D; Xuemei
    Int Urol Nephrol; 2022 Nov; 54(11):2949-2957. PubMed ID: 35579781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system.
    Gatti M; Fusaroli M; Raschi E; Moretti U; Poluzzi E; De Ponti F
    Expert Opin Drug Saf; 2021 Nov; 20(11):1421-1431. PubMed ID: 34280062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-glucose cotransporter-2 inhibitors and cardiovascular safety profile: a pharmacovigilance analysis of the US food and drug administration adverse event reporting system.
    Zhang L; Pan C; Yang X; Jiang D; Cao M
    Expert Opin Drug Saf; 2024 Jun; 23(6):785-792. PubMed ID: 37203199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.